NASDAQ · VRNA
Healthcare · Biotechnology
$106.91
Up+$0.12 (+0.11%)
Updated Sep 10, 2026, 10:58 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
VRNA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning VRNA.
VRNA research
Company profile and research snapshot.
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2025 | HC Wainwright & Co. | Neutral | — |
| Jul 10, 2025 | Wells Fargo | Equal-Weight | — |
| Jul 10, 2025 | BTIG | Neutral | — |
| Jul 9, 2025 | Canaccord Genuity | Hold | — |
| Jul 9, 2025 | Jefferies | Hold | — |
No generated briefing is available yet.
gurufocus.com · Nov 13, 2025
Insights from Jeremy Grantham (Trades, Portfolio)'s Third Quarter 2025 13F Filing Jeremy Grantham (Trades, Portfolio) recently submitted the 13F filing for the
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VRNA.
No results
No recent SID articles mention VRNA.
